Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Viking Therapeutics (VKTX)
NASDAQ:VKTX
Viking Therapeutics (VKTX) Stock Price & Analysis
3,522 Followers
VKTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$8.28 - $99.41
Previous Close$67
Volume4.15M
Average Volume (3M)6.30M
Market Cap
$7.39B
Enterprise Value$6.43B
Total Cash (Recent Filing)$962.98M
Total Debt (Recent Filing)$1.18M
Price to Earnings (P/E)-72.0
Beta1.87
Next Earnings
Jul 24, 2024EPS Estimate
-$0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding110,268,210
10 Day Avg. Volume3,500,572
30 Day Avg. Volume6,302,725
Standard Deviation0.37
R-Squared0.03
Alpha0.07
Financial Highlights & Ratios
Price to Book (P/B)8.15
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-310.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-411.30
Forecast
1Y Price Target
$114.33Price Target Upside70.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Viking Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsViking's VK2735 has demonstrated outstanding efficacy in Phase 2 trials, with results showing substantial weight loss and an excellent safety profile, positioning it as a potential leader in obesity treatment.
Drug Efficacy And SafetyViking's VK2735 showcases a compelling safety/tolerability profile, potentially setting a new standard in the competitive obesity market with its promising drug characteristics.
Market PotentialThe obesity market's vast size and Viking's VK2735's strong market share potential underscore the opportunity for significant growth, given the market's capacity for multiple successful drugs.
Bears Say
Clinical Trial ResultsVKTX shares are trading down following initial efficacy data from Roche's Phase Ib study of dual GLP-1/GIP agonist CT-388.
Competitive PressureWith Novo Nordisk's recent amycretin data, there is potential for a revision in the weight loss benchmark for VK2735.
Drug Development ChallengesViking may need to conduct multiple, multi-year, potentially very expensive studies for NASH approval.
---
Ownership Overview
8.83% Insiders
24.83% Mutual Funds
33.43% Other Institutional Investors
32.90% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VKTX FAQ
What was Viking Therapeutics’s price range in the past 12 months?
Viking Therapeutics lowest stock price was $8.28 and its highest was $99.41 in the past 12 months.
What is Viking Therapeutics’s market cap?
Currently, no data Available
When is Viking Therapeutics’s upcoming earnings report date?
Viking Therapeutics’s upcoming earnings report date is Jul 24, 2024 which is in 67 days.
How were Viking Therapeutics’s earnings last quarter?
Viking Therapeutics released its earnings results on Apr 24, 2024. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.277 by $0.017.
Is Viking Therapeutics overvalued?
According to Wall Street analysts Viking Therapeutics’s price is currently Undervalued.
Does Viking Therapeutics pay dividends?
Viking Therapeutics does not currently pay dividends.
What is Viking Therapeutics’s EPS estimate?
Viking Therapeutics’s EPS estimate is -$0.27.
How many shares outstanding does Viking Therapeutics have?
Viking Therapeutics has 110,268,210 shares outstanding.
What happened to Viking Therapeutics’s price movement after its last earnings report?
Viking Therapeutics reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.277. Following the earnings report the stock price went up 5.824%.
Which hedge fund is a major shareholder of Viking Therapeutics?
Among the largest hedge funds holding Viking Therapeutics’s share is Viking Global Investors LP. It holds Viking Therapeutics’s shares valued at 90M.
---
Viking Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$114.33 (70.64% Upside)
$114.33 (70.64% Upside)
Blogger Sentiment
Bullish
VKTX Sentiment 94%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 3.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 3.6%
Last 30 Days ▲ 3.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
174.47%
12-Months-Change
Fundamentals
Return on Equity
-17.55%
Trailing 12-Months
Asset Growth
541.19%
Trailing 12-Months
Company Description
Viking Therapeutics
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The company's clinical program VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.
---
VKTX Earnings Call
Q1 2024
0:00 / 0:00
---
VKTX Stock 12 Month Forecast
Average Price Target
$114.33
▲(70.64% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Crispr Therapeutics AG
―
Ionis Pharmaceuticals
―
Sarepta Therapeutics
―
Best Analysts Covering VKTX
1 Year
1 Year Success Rate
14/15 ratings generated profit
1 Year Average Return
+243.27%
reiterated a buy rating 24 days ago
Copying Naz Rahman's trades and holding each position for 1 Year would result in 93.33% of your transactions generating a profit, with an average return of +243.27% per trade.
---